Navigation Links
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Date:1/7/2014

HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures.

The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.

"Bellicum is well positioned within the highly promising field of cellular immunotherapy with a technology that provides control over cells after they have been administered to the patient," said Bellicum CEO Tom Farrell. "This funding will be used to advance our two clinical programs in leukemia/lymphoma and prostate cancer, and launch studies in additional indications where there is urgent need for safer and more effective cell therapies."

Bellicum's two lead clinical development programs utilize the Company's unique ability to control cell therapies once inside the body. BPX-501 T cells contain the Company's CaspaCIDe™ gene "safety switch," enabling physicians to eliminate transplanted cells in the event they become harmful to the patient. The product is being evaluated in a Phase I/II study to reduce or eliminate Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell transplant.

BPX-201 dendritic cells contain the Company's DeCIDe® gene "on switch," which enables physicians to strategically target immune activation for a more potent anti-tumor effect. It is being evaluated in a Phase I clinical trial in patients with metastatic castrate-resistant prostate cancer.

About Bellicum Pharmaceuticals

Bellicum is dedicated to developing safer and more effective cell therapies to treat cancers and other serious, life-threatening diseases. The Company's cell therapies are engineered with a gene "switch" that enables physicians to activate or eliminate cells once inside the body to improve safety and efficacy. Bellicum is advancing clinical programs in cellular transplants to reduce or eliminate Graft versus Host Disease, and in prostate cancer with a potentially more potent immunotherapy. For more information please visit www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
5. Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
7. Global Radiopharmaceuticals Market Report 2013 - 2018
8. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
9. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
10. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
11. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):